期刊
CURRENT OPINION IN GENETICS & DEVELOPMENT
卷 52, 期 -, 页码 13-21出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.gde.2018.05.001
关键词
-
资金
- Allen Distinguished Investigator Award from the Paul G. Allen Frontiers Group
- Thorek Memorial Foundation
- US National Institutes of Health (NIH) [R01DA036865, R21NS103007, R33DA041878, U01HG007900, UM1HG009428, R41GM119914, P30AR066527]
- NIH Biotechnology Training Grant [T32GM008555]
- NIH Predoctoral Fellowship [F31NS105419]
- NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG007900, UM1HG009428] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008555, R41GM119914] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS103007, F31NS105419] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON DRUG ABUSE [R01DA036865] Funding Source: NIH RePORTER
The ability to reprogram cell lineage specification through the activity of master regulatory transcription factors has transformed disease modeling, drug screening, and cell therapy for regenerative medicine. Recent advances in the engineering of synthetic transcription factors to modulate endogenous gene expression networks and chromatin states have generated a new set of tools with unique advantages to study and enhance cell reprogramming methods. Several studies have applied synthetic transcription factors in various cell reprogramming paradigms in human and murine cells. Moreover, the adaption of CRISPR-based transcription factors for high-throughput screening will enable the systematic identification of optimal factors and gene network perturbations to improve current reprogramming protocols and enable conversion to more diverse, highly specified, and mature cell types. The rapid development of next-generation technologies with more robust and versatile functionality will continue to expand the application of synthetic transcription factors for cell reprogramming.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据